Getting some good news for a change, Johnson & Johnson ranks fourth among all companies in Newsweek's annual Green Rankings, ahead of other pharmaceuticals that made the top 100, including: Baxter, BMS, Allergan, Pfizer, Abbott, Lilly, Merck, and Hospira.
At the Bioprocess International Conference in Raleigh this week, keynote speaker Paul McKenzie showed that he is taking some of the thinking that he had brought to BMS (read on for a 2007 cover story interview touching on this work) to Centocor, only now he is moving the effort...
Sadly, this year will bring bad news, in the form of pink slips, for thousands of U.S. workers in a number of industries, as The Guardian recently reported (Click here for a sobering update). BMS leads the pharma pack just now.
GSK just announced today that it would be eliminating 900 jobs at its facility in Cidra, Puerto Rico. More from the International Herald Tribune. But Pharmalot reports that BMS will be announcing major cuts in December. Unfortunately, it is far from the only pharma or bio company in job-cutting mode.
I hate posting news like this. BMS plans to cut staff later this year, mainly in "back office" and "infrastructure" positions (translation: IT, manufacturing and operations?) More from CNN But this morning, Bloomberg reports that J&J also plans to reduce its workforce by 4% this year. More from this morning's news.
The Leadership Sphere blog just reviewed the classic business book "Good to Great," with some insights on leaders and one pharma industry leader in particular. The best leaders combine personal humility with intense professional will and resolve.
We'd developed an RSS feed of Bloomberg and AP clips pertinent to pharma, but let it slide a bit, due to technical issues and the fact that Bloomberg et al. didn't cover the drug industry (at least on TV) as much as they generally do, in May.
BMS had a good day yesterday: courts upheld its patent for Plavix (a $6-billion world market) and blocked Apotex's generic version, while FDA announced that it would accelerate review of BMS's new breast cancer drug. Bloomberg aired a report on all this yesterday. Watch the clip here.
Yesterday's FDA panel rejection of Sanofi's weight loss drug Acomplia could mean trouble ahead for Pfizer and Merck, which are now in Phase III testing of drugs with similar modes of action (targeting endocannabinoid receptors), The Science Daily reported yesterday.